Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan

Author(s): Ibrahim Sari, Hakan Cam, M. Sait Dag, Erdal Durmus, Tarik Kivrak, Kursat Tigen, Vedat Davutoglu

Journal Name: Current Drug Safety

Volume 8 , Issue 4 , 2013

Become EABM
Become Reviewer


Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.

Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [282 - 283]
Pages: 2
DOI: 10.2174/1574886319999990001
Price: $65

Article Metrics

PDF: 22